EditorialKommentarLeitlinie
Not Just Another Reporting Guideline? Here’s Why READUS-PV is a Major Step Forward
Drug Safety · 2024
DOI: 10.1007/s40264-024-01441-5 ↗Kurz gefasst
Editorial in der Zeitschrift Drug Safety, 2024. Verfasst von Yoon K Loke. Beteiligte Einrichtung: Norwich Medical School, University of East Anglia, Norwich, NR4 7TJ, UK. y.loke@uea.ac.uk. Hauptthemen laut MEDLINE: Guidelines as Topic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 13 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Guidelines as TopicHumansAdverse Drug Reaction Reporting SystemsDrug-Related Side Effects and Adverse ReactionsPeriodicals as Topic
Autor:innen und Institutionen
- Norwich Medical School, University of East Anglia, Norwich, NR4 7TJ, UK. y.loke@uea.ac.uk.
Zitieren
APA
Loke, Y. K. (2024). Not Just Another Reporting Guideline? Here’s Why READUS-PV is a Major Step Forward. Drug Safety. https://doi.org/10.1007/s40264-024-01441-5
Vancouver
Loke YK. Not Just Another Reporting Guideline? Here’s Why READUS-PV is a Major Step Forward. Drug Safety. 2024. doi:10.1007/s40264-024-01441-5
BibTeX
@article{Loke2024,
author = {Loke, Yoon K},
title = {Not Just Another Reporting Guideline? Here’s Why READUS-PV is a Major Step Forward},
journal = {Drug Safety},
year = {2024},
doi = {10.1007/s40264-024-01441-5}
}
EUVIMED